Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study

Dr Herbert Ho Fung Loong reports on key results from ESMO Congress 2023 on LBA4 – Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC
Simultaneous publication in the NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2309457

Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org

Take the opportunity to connect and share this video with your friends and family if you find it useful.